8.590 9.77%

인기 키워드

Click Each Keyword to Figure Out More

Epithelial Use Cisplatin Anticancer Prognosis Blood Note Syndrome Sensitizes Ultrasound Induction Node Expansion Invasive Exhibit Car Cutaneous Improve Lymph Screening Amg First-in-human Resection Can Pharmacodynamic Negative Phenotype Confers Doe Regulator Transcriptomic Paclitaxel Bone Woman Index Metabolism Ib Natural Design Ib/ii Precursor Benefit Change Oncolytic Colon Small-cell Aurora Biopsy Alpha Temozolomide Innate Metformin High Dose-escalation Cll Fibrosis System Antibody-drug Comparison Parp Induces Cohort Significance Hodgkin Residual Comprehensive Single-cell Group Next-generation Future Control Learning Proliferation Diagnostic Hpv Cell-free Cetuximab High-grade Tissue Grade Hope Microsatellite Window Locally Cellular Functional Dual Ibrutinib Tumor-infiltrating Candidate Follicular Angiogenesis Increase Panel Escalation Pi3k Her2 B Bromodomain Poor Intrahepatic Infiltrate Induced Sample Variant Urothelial Homologous Platinum Disseminated Pet Serum Predicting First-in-class Bispecific Synthetic Induce Targetable Ligand Report Enhanced Tomography Deep Mismatch Activating Uveal Profile Antagonist Ezh2 Subset Tp53 Apoptosis Subtyping Vedotin Neoplasm Damage Translational Interaction Aml Sunitinib Highly Rate Carboplatin Intratumoral Utility Systemic Release Ipilimumab Oncogenic Translation Surface Extracellular Trigger Enhance Modulation Administration Directly Deficiency Rituximab Pattern Longitudinal Trastuzumab Abiraterone Lymphocytic Suppression Across Clear Merkel Vulnerability Score Beyond Genetic Kras Gynecologic Characteristic Esophageal Aggressive Palbociclib Carcinogenesis Classifier Prevents Acetate Recombination Prevent Radioresistance Anti-egfr Relevant Exon Central Liquid Everolimus Synergize Hpv-associated Skin Mogamulizumab Biological Il15 Autocrine Endocrine Membrane Cholangiocarcinoma Etoposide Imatinib Radioimmunotherapy Optimized Independent Nsclc Osimertinib D Loop Nomogram Patient-derived Matched Compared Resected Subject Identify Early-phase Value Cycle Program Concurrent Option Doxorubicin Mapk Anaplastic Foxp3 Ewing Germline Radiosensitization Monotherapy Rb1 Fgfr Condition Mutational Neutrophil Margin Manner Multicentric Anti-gd2 Alk Marrow Instability Histone Mitochondrial Number Fact Cluster Exercise Acid Radiomics Alone Previously Hcc Potentially Injection Aberration Single Bet Host Potentiates Capecitabine At-risk Macroglobulinemia Pharmacokinetics Trabectedin Positron Gastroesophageal Improved Synergistic Adoptive Abscopal Early-stage Il6 Discovery Transition Vesicle Osteosarcoma Transplantation Nab-paclitaxel Difference Suppressor Bortezomib Silencing Akt Hsp90 Hdac Resonance Individual Experimental Esophagogastric Activated Magnetic Amplification Infection Liver Quantitative Diagnosis Nervous Prior Complete Nrg1 Surrogate Origin Myelodysplastic Dendritic State Prodrug Sorafenib Acquired Chemoradiation Intrinsic Regulation Tolerability Deplete Validated Transcriptional Double-blind Classification Effector Age Ar-v567es Myelofibrosis Vaccination Liposomal Time Arginine Surveillance Normal Action Cancer-letter Gemcitabine Emission Untreated Medicine Lncrna Differentiated Distinguishing Mutant Radiation-induced Endometrial Selectively Robust Antigen-specific Cooperate Endoscopic Significant Soft-tissue Intracranial Line Vegf-a Defines Rapamycin Gefitinib Finding Chemoresistance Mortality Heel Neratinib Alisertib Their Egfr-tki Yield Dilution Incidence Immunosuppression Degrader Paradigm Opportunity Affect Genotyping Mr Synthesis Testing Viral Ar Right Diversity Hif-2 Influence Space Polymorphism Carcinoma-associated Reduced Debio Test Esr1 Contrast-enhanced Copy Property Distribution Modifies Current Genetics Assay Identified Sodium Concomitant Act Inhibit Long-term Mycosis Vegfr Degradation Cytarabine Promoter Chemoradiotherapy Chemotherapeutic Overcomes Contribute Modulator Bcl-2 Initiate Immuno-pet Mirnas Multiparametric Vitamin Engagement Pazopanib Associate Accuracy Density Treatment-naïve Application Prexasertib Farnesyl Contrast Domain Particle Junction Nonmetastatic Dependent Evolution Block Flt3 Kaposi Integration Mucosal Inhibiting Enhancing Insulin-like Phosphatase Evaluating Guadecitabine Nuclear Predictor Deacetylase Smad7 Data Fibroblast Pharmacokinetic Standard Local Adolescent Post Platinum-resistant Exploitation Cytotoxicity Dopamine Disparity Senescence Image Glasdegib Blood-brain Generation Adaptive Granulosa Braf-mutant Contribution Telomerase Monoclonal Mek Preoperative Spectrum Multi-center Fatty Evasion Flash Crosstalk Dll3 Gd2-specific Carfilzomib Contributing Inform Mesothelioma Mesenchymal Prevention Clonotypic Sex Systhers Medulloblastoma Consensus Tremelimumab Atr Lapatinib Evolutionary Cd19 Microrna Emtansine Leiomyosarcoma Brca1 Fulvestrant Arm Synthase Spatially Review Ercc1 Sentinel Cd4 Pten Effectiveness Cancer-induced No Epidermal Igf1r Selinexor Rapid Salivary Tumorigenesis Nodule Ido Immunologic Glutamine Tkis Dosing Than Stereotactic Anti-cd38 Activator Extraterminal Promise Overexpression Focus Ca19-9 Mirna Peptide Pancreas Antileukemic Vemurafenib Postoperative Panobinostat Volume Enables Calcium High-dose Viability Older Isocitrate Management Event Regimen Go Feedback Rechallenge Igm Ctdna Undergoing Relationship Pharmacologic Regression Demonstrates Dicer1 Mass Cyclophosphamide Somatostatin Active Culture Letrozole Nk Pharmacogenomic Megakaryocyte Regorafenib Il12 Chemosensitivity Fungoides Notch Estrogen Dexamethasone Transgenic Evidence Machine Vascular Genome Surgical Multi-omics Importance Followed Shift Young Forecast Pathologic Chk1 Dabrafenib High-throughput Critical Protumorigenic Gm-csf Vulnerable Provides Secretion Following Vaccinia Tmb Presentation Cancer-response Persistence First Pemetrexed Administered Ionizing Personalized Somatic Resistant Bcg Transcription Pd1 Antagonism Anal Cd19car-t Trametinib Nerve Exclusion Activates Hla Exchange Waldenström Cxcr4 Memory Hepatitis Network Regulates Pegylated From Liposarcoma On-target Meta-analysis Intensive Advantage Smad4 Infusion Course Related Immunomodulation Neoaltto Sheath Hnscc Suppress Prevalence Inverse Organoid Rational Transcriptome Meningioma Distant Gland Adverse Neoplastic Foster Transferase T-all Cabozantinib Docetaxel Allogeneic Stem-like Radiosensitizes Transplant Er Facilitates Cisplatin-induced Barrier Complex Minimally Follow-up Misclassification Low Feature Uterine Near-infrared Remission Body Chemokine End Hypoxia Fluorescence-guided Enteropathy Overcome Serous Depletion Dock4 Retraction Initiation Intermediate-risk Pontine Vorinostat Formation Disruption Radiosensitivity Fluorescence Lead Notch1 Suppresses

People also search for: Nature Reviews Cancer, Journal of Clinical Oncology, Cancer Cell, Cell Host and Microbe, Drug Resistance Updates, more.

Clinical Cancer Research - 임팩트 팩터 Journal Impact

Clinical Cancer Research 임팩트 팩터 : 8.590 (2020 최신 데이터). 피인용지수 혹은 임팩트 팩터는 자연과학·사회과학 분야의 학술 잡지를 대상으로 삼고, 그 잡지의 영향도를 재는 지표다. 임팩트 팩터 는 2 년 전 (2017-2018) 동안 저널에 발표 된 논문이 특정 연도 (2019) 에받은 평균 인용 횟수를 측정합니다. 과거 임팩트 팩터 데이터와 비교하여 Clinical Cancer Research 9.77% 감소했습니다. Clinical Cancer Research 임팩트 팩터 사 분위: Q1. Clinical Cancer Research의 2-year 임팩트 팩터 외에도 Clinical Cancer Research3-year 임팩트 팩터도 추가 평가에 사용할 수 있습니다.

9.5 ~ 10.0


1/2


Clinical Cancer Research - 2020-21 임팩트 팩터 예측

50% 과학자들은 Clinical Cancer Research 임팩트 팩터 2019-20가 9.5 ~ 10.0 범위에있을 것으로 예상합니다. 영향 요인 추세 예측 시스템은 학술 연구자들이 군중의 지혜를 통해 미래의 저널 영향과 성과를 예측할 수 있도록 개방적이고 투명하며 간단한 플랫폼을 제공합니다. 영향 요인 추세 예측 시스템은 비밀 알고리즘, 숨겨진 요인 또는 체계적인 지연없이 정확한 커뮤니티 중심의 데이터를 표시합니다.

Clinical Cancer Research Impact Factor Trend Forecasting System
  • ISSN
  • 10780432
  • 오픈 액세스
  • 출판사
  • American Association for Cancer Research
  • 국가/지역
  • United States
  • 출판 연도
  • 연구 분야
  • Cancer Research (Q1), Oncology (Q1)

학술지 순위